IHC analyses performed on patients with metastatic melanoma, NSCLC, colon cancer, renal cell carcinoma and prostate cancer who underwent PD-1/PD-L1 targeting therapy suggested PD-L1 overexpression as a potential biomarker. This evidence concerns the gene CD274 and metastatic melanoma.